Status:
COMPLETED
Metabolite Levels in Ovarian Cancer Patients Receiving Maintenance PARP Inhibitors
Lead Sponsor:
Mayo Clinic
Conditions:
Ovarian Carcinoma
Eligibility:
FEMALE
Brief Summary
This study evaluates blood samples and compares levels of metabolites (levels of vitamins, carbohydrates, proteins, etc., that are in the blood), before and after the plasma exchange in patients sched...
Detailed Description
PRIMARY OBJECTIVE: I. To determine the extent to which PARP inhibitor (PARPi) treatment reduces systemic levels of mesenchymal stem cell (MSC)-derived cancer support factors in patients with cancer. ...
Eligibility Criteria
Inclusion
- Adults
- Patients with ovarian cancer starting PARP inhibitor treatment
Exclusion
- Patients unwilling to return for blood draws, patients unwilling to continue PARP inhibitor treatment for at least one month
Key Trial Info
Start Date :
April 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 17 2024
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT04917744
Start Date
April 1 2021
End Date
February 17 2024
Last Update
April 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905